NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

(Formerly Max Bupa Health Insurance Company Limited)

Date: May 9, 2022

Ref: NBHI/NSE-COMPL/FY2223/012

To,
General Manager - Listing
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra East,
Mumbai-400051

Ref: ISINs- INE995S08010, INE995S08028

Sub: Information of newspaper publication of financial results for the quarter and year ended March 31, 2022

Dear Sir/Madam,

Further to outcome of Board meeting reported under Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') vide our letter dated May 5, 2022 and pursuant to Regulation 52 (8) read with Regulation 52 (4) of Listing Regulations and SEBI Circular no. SEBI/HO/DDHS/CIR/2021/0000000637 dated October 05, 2021, please find attached e-newspaper publication of May 7, 2022 in Financial Express (English Edition) in respect of the audited financial results of the Company for the quarter and year ended March 31, 2022.

Please take the above information on record.

Thanking you.

For NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Rajat Sharma

Company Secretary

Address: 14th Floor, Capital Cyberscape, Sector 59, Gurugram, Haryana 122102 **FINANCIAL EXPRESS**

• FIRST EV LAUNCH IN THIS QUARTER

TVS Motor planning ₹700-cr capex for FY23

SAJAN C KUMAR Chennai, May 6

TVS MOTOR COMPANY is planning a ₹700-crore capex for FY23 which will be utilised primarily for product development and capacity expansion, including in the future mobility area.

The company will be rolling out a slew of products for different customer segments on the electrical vehicle (EV) side. The launches will be spread over the next eight quarters, with the first being in the first quarter of FY23.

KN Radhakrishnan, director & CEO of TVS Motor Company, told an earning conference call: "We will be launching a series of new products focusing on different customer segments. The company is readying a complete portfolio of two-wheelers and three-wheelers in the range of 5Kw to 25 Kw, which will be hitting the market in the next eight quarters." Emphasising on the EV front, Radhakrishnan said that its e-scooter iQube has 12,000 bookings in



■ The company's e-scooter iQube has 12,000 bookings in the pipeline while it has sold 12,000 units so far, with a presence in 33 cities

■ During FY22, the overall two- and three-wheeler sales grew by 8% at 33,10,000 units as against 30,52,000 units in the year 2020-21

the pipeline while it has sold 12,000 units so far, currently with a presence in 33 cities. "We are expanding our capacity and we will be reaching the 10,000 units per month capacity of iQube by the end of Q1 of FY23. We will continue to expand the capacity throughout the year as we move to more cities," he said, adding that "we intent to cover pan India and go overseas by

end of the fiscal." On the charging front, the company had tied up with Jiobp, Tata Power and CESL.

When asked whether the company has any tie-ups on technology for EV and premium products, he said most of the technology has been developed in-house and that was the big differentiator.

The company had invested significant money in acquiring two e-bike firms in Swiss recently, and pumped in £100 million into Norton Motorcycle Company which it acquired in 2020. "Majority of investments are giving us good returns, the two e-bike companies are now profitable.

Lakshmi Venu takes over as new MD of Sundaram-Clayton

FE BUREAU Chennai, May 6

VENU, LAKSHMI **DAUGHTER** of Venu Srinivasan, has taken over as the managing director of Sundaram-Clayton (SCL), one of India's leading auto components manufacturers. She was the joint MD of SCL, a TVS Group company. The decision to elevate Lakshmi Venu as MD of SCL comes close on the heels of Sudarshan Venu's appointment as MD of TVS Motor

Company on Thursday. Lakshmi Venu who has been leading SCL from the front for over a decade now, has been the lead architect of establishing SCL's

global footprint. Under her leadership, the company took the decision to set up a foundry in the US three years ago in 2019 in Dorchester, South Carolina, at a time when



most US-based customers were looking for on-shore foundry units to reduce supply chain risks.

She has built deep customer relationships with Cummins, Hyundai, Volvo, Paccar and Daimler.

Venu Srinivasan, chairman emeritus, SCL, said, "Lakshmi's focus and dedicated efforts over the last ten years have seen the company do a turnaround in quality, profitability, and building relationship with OEMs."

Coromandel to buy 45% stake in Senegal's BMCC for ₹225 cr

COROMANDEL INTERNATIONAL, **PART** of Murugappa group and one of the largest private phosphatic fertilser manufacturers in the country, is set to acquire 45% equity stake in

Baobab Mining and Chemicals Corporation (BMCC), a rock phosphate mining company based in Senegal, Africa, at an outlay of \$19.6 million (₹150 crore), besides a loan infusion

of a further \$9.7 million (₹75 crore) into BMCC. The acquisition through its subsidiary, Parry Chemicals, is expected to be completed in the second quarter of FY23. -FE BUREAU



Date: May 05, 2022

Place: New Delhi

PNB GILTS LIMITED

(CIN L74899DL1996PLC077120) Regd. Office: 5, Sansad Marg, New Delhi- 110001, Website: www.pnbgilts.com, E-mail: pnbgilts@pnbgilts.com Tel: 011-23325759, 23325779, Fax: 011-23325751, 23325763

_	(, in lacs					
	PARTICULARS	3 MONTHS ENDED 31.03.2022 (Audited)	3 MONTHS ENDED 31.12.2021 (Reviewed)	3 MONTHS ENDED 31.03.2021 (Audited)	YEAR ENDED 31.03.2022 (Audited)	YEAR ENDED 31.03.2021 (Audited)
1.	Total Income from Operations	24,190.63	26,249.16	18,405.75	98,972.19	1,05,197.77
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	5,928.07	(1,608.44)	(307.85)	20,323.82	62,307.32
3.	Net Profit/(Loss) for the period before Tax (after Exceptional and/ or Extraordinary items)	5,924.89	(1,614.11)	(1,180.47)	21,015.10	61,434.70
4.	Net Profit/(Loss) for the period after Tax (after Exceptional and/ or Extraordinary items)	4,905.42	(614.73)	(1,413.67)	16,571.13	45,411.68
5.	Total Comprehensive income for the period [Comprising profit/(loss) for the period (after tax) and Other Comprehensive Income (after tax)]	4,913.87	(609.63)	(1,408.69)	16,494.23	45,385.19
6.	Equity Share Capital	18,001.01	18,001.01	18,001.01	18,001.01	18,001.01
7.	Earnings Per Equity (of Rs. 10/- each) (for continuing and discontinued operations)					
7	Basic:	2.73	(0.34)	(0.79)	9.21	25.23
	Diluted:	2.73	(0.34)	(0.79)	9.21	25.23

Earnings per share for three months are not annualised. . The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulations, 2015. The Full Format of the Quarterly Financial Results are available on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com respectively and on Company's website www.pnbgilts.com.

> (Vikas Goel) MD & CEO

For and on behalf of Board



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

(Formerly known as Max Bupa Health Insurance Company Limited) REGISTRATION NO: 145, DATE OF REGISTRATION WITH IRDAI: FEBRUARY 15, 2010

Health Insurance **Financial Results** Rs in Lakhs

Ch	Particulars	3 months ended/ As at			Year Ended	
SN		March 31, 2022	Dec. 31, 2021	March 31, 2021	March 31, 2022	March 31, 2021
1	Premium Income (Gross) (Note 1)	89,237	66,863	60,051	2,80,997	1,75,078
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(4,785)	(4,379)	(189)	(19,653)	(4,974)
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(4,785)	(4.379)	(189)	(19,653)	(4,974)
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(4,785)	(4,379)	(189)	(19,653)	(4,974)
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] (Note 2)	NA	NA	NA	NA	NA
6	Paid up Equity Share Capital	1,40,860	1,40,642	1,34,973	1,40,860	1,34,973
7	Reserves (excluding Revaluation Reserve)	12,540	12,504	5,679	12,540	5,679
8	Securities Premium Account	12,511	12,501	5,675	12,511	5,675
9	Paid up Debt Capital/ Outstanding Debt (Note 3)	25,000	15,000		25,000	

Additional Disclosures as required under 52(4) of SEBI (LODR) Regulations 2015

NI Destaulant	Tear Eraca				
N Particulars	March 31, 2022	March 31, 2021			
Debt Equity Ratio (Note 4)	0.49	NA			
Debt Service Coverage Ratio (Note 5)	(29.13)	NA			
Interest Service Coverage Ratio (Note 6)	(29.13)	NA			
Outstanding Redeemable Preference Shares (quantity and value)	NA	NA			
Capital Redemption Reserve/ Debenture Redemption Reserve (Note 7)		NA			
Net Worth (Rs. in Lakhs)	50,764	57,668			
Net Profit/(Loss) after Tax (Rs. in Lakhs)	(19,653)	(4,974)			
Earning Per Share					
-Basic Earning/ (Loss) per Share	(1.42)	(0.43)			
-Diluted Earning/ (Loss) per Share	(1.41)	(0.43)			
Current Ratio (Note 8)	0.14	0.17			
O Long Term Debt to Working Capital (Note 9)	(0.15)	NA			
1 Current Liability Ratio (Note 10)	0.89	1.00			
2 Total Debts to Total Assets (Note 11)	0.09	NA			

Notes:

- Premium Income is gross of reinsurance and net of Goods and Service tax.
- The Indian Accounting Standards (Ind As) are not applicable to Insurance Companies in India.
- Disclosure for previous period comparatives are not available since the Company has raised the debt in FY 21-
- Debt Equity Ratio is calculated as Total Borrowings divided by Net worth.
- Debt-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense together with principal repayments of long term debt made during the year. 6. Interest-Service Coverage Ratio is computed as Profit before Interest and Tax divided by Interest expense of
- long term debt. 7. The Company is required to make Debenture Redemption Reserve pursuant to Ministry of Corporate Affairs notification no G.S.R 574 (E) dated August 16, 2019 of Companies (Share Capital and Debentures) rules 2014, however since the Company has incurred losses during the year ended March 31, 2022 no amount
- has been transferred to Debenture Redemption Reserve. Current Ratio is current assets (Cash and bank balance and advances & other assets) divided by current liabilities and provisions.
- 9. Long term debt to working capital is computed as Long term debt divided by the working capital (Working Capital= Current asset-Current liabilities)
- 10. Current Liability Ratio is computed as 'current liabilities and provision' divided by total liabilities. Total liability includes borrowings, current liabilities and provisions.

Year Ended

- 11. Total Debts to Total Assets is total borrowings divided by total assets as per balance sheet.
- 12. Credit Rating: "CARE A stable".
- 13. As per Clause 52(4) of Chapter V of SEBI (listing obligations and Disclosure requirements) 2015, as amended, ratios such as, Bad Debts to Accounts Receivable ratio, Debtors turnover, Inventory turnover, Operating margin and Net Profit margin are not applicable to the company.
- 14. The above is an extract of the detailed format of Financial Results filed with the Stock Exchange under Regulation 52 of the SEBI (Listed Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of Financial Results are available on the Stock Exchange website (www.nseindia.com) and the Company's website (www.nivabupa.com). For the other line items referred in regulation 52 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange (NSE) and can be accessed on the NSE website (www.nseindia.com).

For on and behalf of Board of Directors Krishnan Ramachandran CEO & Managing Director (DIN:08719264)

Insurance is a subject matter of solicitation. Niva Bupa Health Insurance Company Limited (formerly known as Max Bupa Health Insurance Company Limited) (IRDAI Registration Number 1 45). 'Bupa' and 'HEARTBEAT' logo are registered trademarks of their respective owners and are being used by Niva Bupa Health Insurance Company Limited under license. IRDAI Registered Office: C-98, First Floor, Lajpat Nagar, Part 1, New Delhi-110024, Corporate Office: 14th Floor, Capital Cyberscape, Golf Course Extension Road, Sector-59, Gurugram -122011 (Haryana). CIN No. U66000DL2008PLC182918. Customer Helpline No.: 1860-500-8888. Website: www.nivabupa.com financialexp.epap.in New Delhi